Patents by Inventor Matthew Duncan Selby

Matthew Duncan Selby has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11912721
    Abstract: A series of fused pentacyclic imidazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. In particular, the present invention is concerned with 6, 7-dihydro-7, 14-methanobenzimidazo[1, 2-b][2,5]benzodiazocin-5(14H)-one derivatives and analogs thereof.
    Type: Grant
    Filed: November 24, 2020
    Date of Patent: February 27, 2024
    Assignees: UCB Biopharma SRL, Sanofi
    Inventors: Teresa De Haro Garcia, Michael Deligny, Jag Paul Heer, Joanna Rachel Quincey, Mengyang Xuan, Zhaoning Zhu, Daniel Christopher Brookings, Mark Daniel Calmiano, Yves Evrard, Martin Clive Hutchings, James Andrew Johnson, Sophie Jadot, Jean Keyaerts, Malcolm MacCoss, Matthew Duncan Selby, Michael Alan Shaw, Dominique Louis Leon Swinnen, Laurent Schio, Yann Foricher, Bruno Filoche-Romme
  • Publication number: 20220332709
    Abstract: Thiophene derivatives of formula (I) and a pharmaceutically acceptable salt thereof are provided. These compounds have utility for the treatment or prevention of disorders caused by IgE, such as allergy, type 1 hypersensitivity or familiar sinus inflammation.
    Type: Application
    Filed: June 20, 2019
    Publication date: October 20, 2022
    Inventors: Pfrafulkumar Tulshibhai Chovatia, Rickki Lee Connelly, Richard Jeremy Franklin, Gregory William Haslett, Alistair James Henry, James Madden, Judi Charlotte Neuss, Timothy John Norman, Oliver Philps, William Ross Pitt, Konstantinos Rampalakos, Matthew Duncan Selby, Suganthan Selvaratnam, Giancarlo Trani, Zhaoning Zhu
  • Publication number: 20220227764
    Abstract: A series of substituted fused bicyclic imidazole derivatives, including imidazo[1,2-a]pyridine derivatives and analogues thereof, being potent modulators of human IL-17 activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including inflammatory and autoimmune disorders.
    Type: Application
    Filed: June 24, 2020
    Publication date: July 21, 2022
    Inventors: Anne Marie Foley, Fabien Claude Lecomte, James Thomas Reuberson, Matthew Duncan Selby, Richard David Taylor, Paul Jonathan Hickford, Gareth Neil Brace
  • Publication number: 20220073485
    Abstract: A series of functionalised amine derivatives of formula (I) as defined herein, being potent modulators of human IL-17 activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including inflammatory and autoimmune disorders.
    Type: Application
    Filed: November 27, 2019
    Publication date: March 10, 2022
    Inventors: Anne Marie Foley, Jag Paul Heer, Fabien Claude Lecomte, Nathaniel Julius Thomas Monck, Matthew Duncan Selby, Mengyang Xuan, Lihu Yang
  • Publication number: 20210380573
    Abstract: A series of substituted benzimidazol-2-one derivatives, and analogues thereof, being potent modulators of human IL-17 activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including inflammatory and autoimmune disorders.
    Type: Application
    Filed: November 27, 2019
    Publication date: December 9, 2021
    Inventors: Fabien Claude Lecomte, Matthew Duncan Selby
  • Patent number: 11052076
    Abstract: A series of substituted spirocyclic 2-oxoindoline derivatives, and analogues thereof, being potent modulators of human IL-17 activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including inflammatory and autoimmune disorders.
    Type: Grant
    Filed: June 12, 2018
    Date of Patent: July 6, 2021
    Assignee: UCB Biopharma SRL
    Inventors: Gareth Neil Brace, Rose Elizabeth Chappell, Hervé Jean Claude Deboves, Anne Marie Foley, Gregory Foulkes, Elizabeth Pearl Jones, Fabien Claude Lecomte, Joanna Rachel Quincey, Monika-Sarah Elisabeth Dorothea Schulze, Matthew Duncan Selby, Adam Peter Smalley, Richard David Taylor, Robert James Townsend, Zhaoning Zhu
  • Publication number: 20210155637
    Abstract: A series of fused pentacyclic imidazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. In particular, the present invention is concerned with 6,7-dihydro-7,14-methanobenzimidazo[1,2-b][2,5]benzodiazocin-5(14H)-one derivatives and analogs thereof.
    Type: Application
    Filed: November 24, 2020
    Publication date: May 27, 2021
    Inventors: Teresa De Haro Garcia, Michael Deligny, Jag Paul Heer, Joanna Rachel Quincey, Mengyang Xuan, Zhaoning Zhu, Daniel Christopher Brookings, Mark Daniel Calmiano, Yves Evrard, Martin Clive Hutchings, James Andrew Johnson, Sophie Jadot, Jean Keyaerts, Malcolm Mac Coss, Matthew Duncan Selby, Michael Alan Shaw, Dominique Louis Leon Swinnen, Laurent Schio, Yann Foricher, Bruno Filoche-Romme
  • Patent number: 10906919
    Abstract: A series of fused pentacyclic imidazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. In particular, the present invention is concerned with 6,7-dihydro-7,14-methanobenzimidazo[1,2-b][2,5]benzodiazocin-5(14H)-one derivatives and analogs thereof.
    Type: Grant
    Filed: December 14, 2018
    Date of Patent: February 2, 2021
    Assignees: UCB Biopharma SRL, Sanofi
    Inventors: Teresa De Haro Garcia, Michael Deligny, Jag Paul Heer, Joanna Rachel Quincey, Mengyang Xuan, Zhaoning Zhu, Daniel Christopher Brookings, Mark Daniel Calmiano, Yves Evrard, Martin Clive Hutchings, James Andrew Johnson, Sophie Jadot, Jean Keyaerts, Malcolm Mac Coss, Matthew Duncan Selby, Michael Alan Shaw, Dominique Louis Leon Swinnen, Laurent Schio, Yann Foricher, Bruno Filoche-Romme
  • Publication number: 20200138797
    Abstract: A series of substituted spirocyclic 2-oxoindoline derivatives, and analogues thereof, being potent modulators of human IL-17 activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including inflammatory and autoimmune disorders.
    Type: Application
    Filed: June 12, 2018
    Publication date: May 7, 2020
    Inventors: Gareth Neil Brace, Rose Elizabeth Chappell, Hervé Jean Claude Deboves, Anne Marie Foley, Gregory Foulkes, Elizabeth Pearl Jones, Fabien Claude Lecomte, Joanna Rachel Quincey, Monika-Sarah Elisabeth Dorothea Schulze, Matthew Duncan Selby, Adam Peter Smalley, Richard David Taylor, Robert James Townsend, Zhaoning Zhu
  • Publication number: 20190367535
    Abstract: A series of fused pentacyclic imidazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. In particular, the present invention is concerned with 6,7-dihydro-7,14-methanobenzimidazo[1,2-b][2,5]benzodiazocin-5(14H)-one derivatives and analogs thereof.
    Type: Application
    Filed: December 14, 2018
    Publication date: December 5, 2019
    Inventors: Teresa De Haro Garcia, Michael Deligny, Jag Paul Heer, Joanna Rachel Quincey, Mengyang Xuan, Zhaoning Zhu, Daniel Christopher Brookings, Mark Daniel Calmiano, Yves Evrard, Martin Clive Hutchings, James Andrew Johnson, Sophie Jadot, Jean Keyaerts, Malcolm Mac Coss, Matthew Duncan Selby, Michael Alan Shaw, Dominique Louis Leon Swinnen, Laurent Schio, Yann Foricher, Bruno Filoche-Romme
  • Patent number: 10202405
    Abstract: A series of fused pentacyclic imidazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. In particular, the present invention is concerned with 6,7-dihydro-7,14-methanobenzimidazo[1,2-b][2,5]benzodiazocin-5(14H)-one derivatives and analogs thereof.
    Type: Grant
    Filed: October 2, 2015
    Date of Patent: February 12, 2019
    Assignee: UCB Biopharma SPRL
    Inventors: Teresa De Haro Garcia, Michael Deligny, Jag Paul Heer, Joanna Rachel Quincey, Mengyang Xuan, Zhaoning Zhu, Daniel Christopher Brookings, Mark Daniel Calmiano, Yves Evrard, Martin Clive Hutchings, James Andrew Johnson, Sophie Jadot, Jean Keyaerts, Malcolm Mac Coss, Matthew Duncan Selby, Michael Alan Shaw, Dominique Louis Leon Swinnen, Laurent Schio, Yann Foricher, Bruno Filoche-Romme
  • Patent number: 10004737
    Abstract: A series of substituted benzimidazole, imidazo[1,2-?]pyridine and pyrazolo[1,5-?]pyridine derivatives, and analogs thereof, being potent modulators of human TNF? activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Grant
    Filed: December 8, 2014
    Date of Patent: June 26, 2018
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Julien Alistair Brown, Mark Daniel Calmiano, Elizabeth Pearl Jones, Boris Kroeplien, James Thomas Reuberson, Matthew Duncan Selby, Michael Alan Shaw, Zhaoning Zhu
  • Patent number: 9932343
    Abstract: A series of tricyclic benzimidazole derivatives, in particular dihydro-1H-imidazo [1,2-a]benzimidazole, dihydro-1H-pyrrolo [1,2-a]benzimidazole, dihydro-1H-pyrazino[1,2-a]benzimidazole, dihydro-1H-[1,4]oxazino[4,3-a]benzimidazole and dihydrothiazolo[3,4-a]benzimidazolem, and analogs thereof, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Grant
    Filed: December 8, 2014
    Date of Patent: April 3, 2018
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Rikki Peter Alexander, Mark Daniel Calmiano, Sabine Defays, Veronique Durieu, Michael Deligny, Jag Paul Heer, Victoria Elizabeth Jackson, Jean Keyaerts, Boris Kroeplien, Malcolm Mac Coss, Yogesh Anil Sabnis, Matthew Duncan Selby, Dominique Louis Leon Swinnen, Nathalie Van Houtvin, Zhaoning Zhu, Uwe Heinelt, Volkmar Wehner
  • Patent number: 9868749
    Abstract: A series of substituted benzimidazole, imidazo[1,2-a]pyridine and pyrazolo[1,5-a]pyridine derivatives, and analogues thereof, being potent modulators of human TNF? activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Grant
    Filed: December 8, 2014
    Date of Patent: January 16, 2018
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Rikki Peter Alexander, Jonathan Mark Bentley, Gareth Neil Brace, Daniel Christopher Brookings, Prafulkumar Tulshibhai Chovatia, Hervé Jean Claude Deboves, Craig Johnstone, Elizabeth Pearl Jones, Boris Kroeplien, Fabien Claude Lecomte, James Madden, Craig Miller, John Robert Porter, Matthew Duncan Selby, Michael Alan Shaw, Darshan Gunvant Vaidya, Ian Andrew Yule
  • Publication number: 20170305932
    Abstract: A series of fused pentacyclic imidazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. In particular, the present invention is concerned with 6,7-dihydro-7,14-methanobenzimidazo[1,2-b][2,5]benzodiazocin-5(14H)-one derivatives and analogs thereof.
    Type: Application
    Filed: October 2, 2015
    Publication date: October 26, 2017
    Inventors: Teresa De Haro Garcia, Michael Deligny, Jag Paul Heer, Joanna Rachel Quincey, Mengyang Xuan, Zhaoning Zhu, Daniel Christopher Brookings, Mark Daniel Calmiano, Yves Evrard, Martin Clive Hutchings, James Andrew Johnson, Sophie Jadot, Jean Keyaerts, Malcolm Mac Coss, Matthew Duncan Selby, Michael Alan Shaw, Dominique Louis Leon Swinnen, Laurent Schio, Yann Foricher, Bruno Filoche-Romme
  • Publication number: 20170128445
    Abstract: A series of substituted benzimidazole, imidazo[1,2-?]pyridine and pyrazolo[1,5-?]pyridine derivatives, and analogues thereof, being potent modulators of human TNF? activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Application
    Filed: December 8, 2014
    Publication date: May 11, 2017
    Inventors: Julien Alistair Brown, Mark Daniel Calmiano, Elizabeth Pearl Jones, Boris Kroeplien, James Thomas Reuberson, Matthew Duncan Selby, Michael Alan Shaw, Zhaoning Zhu
  • Patent number: 9550737
    Abstract: A series of benzimidazole derivatives, being potent modulators of human TNF? activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Grant
    Filed: June 11, 2013
    Date of Patent: January 24, 2017
    Assignee: UCB Biopharma SPRL
    Inventors: Daniel Christopher Brookings, Mark Daniel Calmiano, Ellen Olivia Gallimore, Helen Tracey Horsley, Martin Clive Hutchings, James Andrew Johnson, Boris Kroeplien, Fabien Claude Lecomte, Martin Alexander Lowe, Timothy John Norman, John Robert Porter, Joanna Rachel Quincey, James Thomas Reuberson, Matthew Duncan Selby, Michael Alan Shaw, Zhaoning Zhu, Anne Marie Foley
  • Patent number: 9475820
    Abstract: A series of imidazo[1,2-a]pyrazine derivatives, being potent modulators of human TNF? activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Grant
    Filed: July 5, 2013
    Date of Patent: October 25, 2016
    Assignee: UCB Biopharma SPRL
    Inventors: Jonathan Mark Bentley, Daniel Christopher Brookings, Julien Alistair Brown, Thomas Paul Cain, Laura Jane Gleave, Alexander Heifetz, Victoria Elizabeth Jackson, Craig Johnstone, Deborah Leigh, James Madden, John Robert Porter, Matthew Duncan Selby, Zhaoning Zhu
  • Publication number: 20160304523
    Abstract: A series of tricyclic benzimidazole derivatives, in particular dihydro-1H-imidazo [1,2-a]benzimidazole, dihydro-1H-pyrrolo [1,2-a]benzimidazole, dihydro-1H-pyrazino[1,2-a]benzimidazole, dihydro-1H-[1,4]oxazino[4,3-a]benzimidazole and dihydrothiazolo[3,4-a]benzimidazolem, and analogues thereof, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Application
    Filed: December 8, 2014
    Publication date: October 20, 2016
    Inventors: Rikki Peter Alexander, Mark Daniel Calmiano, Sabine Defays, Veronique Durieu, Michael Deligny, Jag Paul Heer, Victoria Elizabeth Jackson, Jean Keyaerts, Boris Kroeplien, Malcolm Mac Coss, Yogesh Anil Sabnis, Matthew Duncan Selby, Dominique Louis Leon Swinnen, Nathalie Van Houtvin, Zhaoning Zhu, Uwe Heinelt, Volkmar Wehner
  • Publication number: 20160297837
    Abstract: A series of substituted benzimidazole, imidazo[1,2-a]pyridine and pyrazolo[1,5-a]pyridine derivatives, and analogues thereof, being potent modulators of human TNF? activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Application
    Filed: December 8, 2014
    Publication date: October 13, 2016
    Inventors: Rikki Peter Alexander, Jonathan Mark Bentley, Gareth Neil Brace, Daniel Christopher Brookings, Praful Tulshi Chovatia, Hervé Jean Claude Deboves, Craig Johnstone, Elizabeth Pearl Jones, Boris Kroeplien, Fabien Claude Lecomte, James Madden, Craig Miller, John Robert Porter, Matthew Duncan Selby, Michael Alan Shaw, Darshan Gunvant Vaidya, Ian Andrew Yule